Invokana joins Forxiga in European SGLT2 inhibitor space
This article was originally published in Scrip
The European Commission has approved Invokana (canagliflozin) from Janssen-Cilag (J&J) for type 2 diabetes, making it the second SGLT2 inhibitor to reach the European market after AstraZeneca/Bristol-Myers Squibb's Forxiga (dapagliflozin) was approved a year ago (scripintelligence.com, 15 November 2012).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.